Literature DB >> 17416541

Alternative splicing in cancer: noise, functional, or systematic?

Rolf I Skotheim1, Matthias Nees.   

Abstract

Pre-messenger RNA splicing is a fine-tuned process that generates multiple functional variants from individual genes. Various cell types and developmental stages regulate alternative splicing patterns differently in their generation of specific gene functions. In cancers, splicing is significantly altered, and understanding the underlying mechanisms and patterns in cancer will shed new light onto cancer biology. Cancer-specific transcript variants are promising biomarkers and targets for diagnostic, prognostic, and treatment purposes. In this review, we explore how alternative splicing cannot simply be considered as noise or an innocent bystander, but is actively regulated or deregulated in cancers. A special focus will be on aspects of cell biology and biochemistry of alternative splicing in cancer cells, addressing differences in splicing mechanisms between normal and malignant cells. The systems biology of splicing is only now applied to the field of cancer research. We explore functional annotations for some of the most intensely spliced gene classes, and provide a literature mining and clustering that reflects the most intensely investigated genes. A few well-established cancer-specific splice events, such as the CD44 antigen, are used to illustrate the potential behind the exploration of the mechanisms of their regulation. Accordingly, we describe the functional connection between the regulatory machinery (i.e., the spliceosome and its accessory proteins) and their global impact on qualitative transcript variation that are only now emerging from the use of genomic technologies such as microarrays. These studies are expected to open an entirely new level of genetic information that is currently still poorly understood.

Entities:  

Mesh:

Year:  2007        PMID: 17416541     DOI: 10.1016/j.biocel.2007.02.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  98 in total

1.  Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.

Authors:  Colleen L Doçi; Tanmayi P Mankame; Alexander Langerman; Kelly R Ostler; Rajani Kanteti; Timothy Best; Kenan Onel; Lucy A Godley; Ravi Salgia; Mark W Lingen
Journal:  Int J Gynecol Pathol       Date:  2012-01       Impact factor: 2.762

Review 2.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

3.  Living or dying by RNA processing: caspase expression in NSCLC.

Authors:  Ganesh Shankarling; Kristen W Lynch
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

Review 4.  Aberrant RNA splicing and its functional consequences in cancer cells.

Authors:  James D Fackenthal; Lucy A Godley
Journal:  Dis Model Mech       Date:  2008 Jul-Aug       Impact factor: 5.758

Review 5.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

6.  Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.

Authors:  Yundong He; Ji Lu; Zhenqing Ye; Siyuan Hao; Liewei Wang; Manish Kohli; Donald J Tindall; Benyi Li; Runzhi Zhu; Liguo Wang; Haojie Huang
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

7.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.

Authors:  Bryan P Toole
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms.

Authors:  Yongchun Wang; Jeanne Kowalski; Hua-Ling Tsai; Radharani Marik; Nijaguna Prasad; Helina Somervell; Pang-Kuo Lo; Lauren E Sangenario; Lars Dyrskjot; Torben F Orntoft; William H Westra; Alan K Meeker; James R Eshleman; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

Review 9.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

10.  Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors.

Authors:  Barbara Patócs; Krisztina Németh; Miklós Garami; Gabriella Arató; Ilona Kovalszky; Miklós Szendrői; György Fekete
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.